We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+92.45%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$366M
AUM Growth
+$124M
Cap. Flow
-$37.7M
Cap. Flow %
-10.29%
Top 10 Hldgs %
94.54%
Holding
16
New
–
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
TRVI icon
Trevi Therapeutics
TRVI
+$396K
2
REPL icon
Replimune Group
REPL
+$381K
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$112K
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$10.3K

Top Sells

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$24.3M
2
GOSS icon
Gossamer Bio
GOSS
+$12M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$1.31M
4
EPIX
ESSA Pharma
EPIX
+$912K
5
CDTX
Cidara Therapeutics
CDTX
+$9.46K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$132M 36.13%
5,344,971
+21,516
+0.4% +$381K
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$80.5M 22.01%
2,975,582
+6,000
+0.2% +$112K
GOSS icon
3
Gossamer Bio
GOSS
$66.5M
$43.2M 11.8%
3,320,608
-955,118
-22% -$12M
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.42B
$25.5M 6.98%
844,680
– –
IMUX icon
5
Immunic
IMUX
$182M
$16.6M 4.55%
137,149
– –
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13.6M 3.71%
2,602,739
+2,329
+0.1% +$10.3K
EPIX
7
DELISTED
ESSA Pharma
EPIX
$9.28M 2.54%
1,497,448
-192,400
-11% -$912K
TRVI icon
8
Trevi Therapeutics
TRVI
$2.49B
$9.05M 2.48%
1,375,907
+112,499
+9% +$396K
BEAM icon
9
Beam Therapeutics
BEAM
$2.58B
$8.48M 2.32%
302,821
– –
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$7.4M 2.02%
100,262
-146
-0.1% -$9.46K
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.89M 1.61%
999,364
– –
KYNB
12
Kyntra Bio
KYNB
$28.5M
$5.29M 1.45%
5,226
– –
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.66M 1%
529,965
– –
PRVL
14
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$2.79M 0.76%
187,538
-85,269
-31% -$1.31M
PVLA
15
Palvella Therapeutics
PVLA
$1.98B
$2.33M 0.64%
9,384
– –
TBIO
16
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-2,437,603
Closed -$24.3M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2020 Portfolio in Review

As of Q2 2020, Omega Fund Management held 16 positions worth $366M, up 51% from $242M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Omega Fund Management withdrew a net $37.7M in Q2 2020, closing 1 position and reducing 4 holdings. Its most notable exit was Translate Bio, Inc. Common Stock, an estimated $24.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Omega Fund Management added an estimated $396K to Trevi Therapeutics.

  • Omega Fund Management added most to Trevi Therapeutics in Q2 2020, an estimated $396K increase.
  • Omega Fund Management's biggest Q2 2020 reduction was Gossamer Bio, cutting an estimated $12M.
  • Omega Fund Management fully exited Translate Bio, Inc. Common Stock in Q2 2020, selling an estimated $24.3M.
  • Omega Fund Management's ten largest holdings make up 95% of its $366M portfolio in Q2 2020.
  • Omega Fund Management opened 0 new positions and closed 1 in Q2 2020.
  • Omega Fund Management's portfolio value rose 51% quarter-over-quarter to $366M.

Based on Omega Fund Management's 13F filing for Q2 2020, filed 17 Aug 2020.